Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor-Reference-Cited by-同舟云学术

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Published:2023-05 Issue: Volume:172 Page:65-71
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

McNamara Blair,Harold Justin,Manavella Diego,Bellone Stefania,Mutlu Levent,Hartwich Tobias Max Philipp,Zipponi Margherita,Yang-Hartwich Yang,Demirkiran Cem,Verzosa Miguel Skyler Z.,Yang Kevin,Choi Jungmin,Dong Weilai,Buza Natalia,Hui Pei,Altwerger Gary,Huang Gloria S.,Andikyan Vaagn,Clark Mitchell,Ratner Elena,Azodi Masoud,Schwartz Peter E.,Burton Elizabeth A.,Inagaki Hiroaki,Albers Aaron,Zhang Chao,Bollag Gideon,Schlessinger Joseph,Santin Alessandro D.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference17 articles.

1. Clinical management of uterine sarcomas;Amant;Lancet Oncol.,2009

2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II study;Hensley;Gynecol. Oncol.,2008

3. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial;Hensley;J. Clin. Oncol.,2002

4. Gynecologic oncology group (GOG) study, phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a gynecologic oncology group (GOG) study;Look;Gynecol. Oncol.,2004

5. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study;Omura;J. Clin. Oncol.,1985

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort;Biomedicines;2023-11-22